We are live on ! Find out more
MIST icon

Milestone Pharmaceuticals

79 hedge funds and large institutions have $53.6M invested in Milestone Pharmaceuticals in 2025 Q4 according to their latest regulatory filings, with 28 funds opening new positions, 21 increasing their positions, 9 reducing their positions, and 9 closing their positions.

New
Increased
Maintained
Reduced
Closed

211% more first-time investments, than exits

New positions opened: 28 | Existing positions closed: 9

133% more repeat investments, than reductions

Existing positions increased: 21 | Existing positions reduced: 9

30% more funds holding

Funds holding: 6179 (+18)

0% more funds holding in top 10

Funds holding in top 10: 22 (0)

9.06% less ownership

Funds ownership: 40.17%31.11% (-9.1%)

22% less capital invested

Capital invested by funds: $68.3M → $53.6M (-$14.7M)

73% less call options, than puts

Call options by funds: $667K | Put options by funds: $2.47M

Holders
79
Holders Change
+18
Holders Change %
+29.51%
% of All Funds
0.96%
Holding in Top 10
2
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.02%
New
28
Increased
21
Reduced
9
Closed
9
Calls
$667K
Puts
$2.47M
Net Calls
-$1.81M
Net Calls Change
-$1.59M
Name Holding Trade Value Shares
Change
Change in
Stake
PBM
1
Propel Bio Management
California
$8.32M -$2.17M -1,006,569 -20%
Adage Capital Partners
2
Adage Capital Partners
Massachusetts
$5.68M -$8.97M -4,165,963 -60%
RI
3
RTW Investments
New York
$5.06M
Marshall Wace
4
Marshall Wace
United Kingdom
$3.35M +$2.65M +1,231,793 +290%
Two Sigma Investments
5
Two Sigma Investments
New York
$3.06M +$1.83M +847,910 +127%
SAM
6
Simplify Asset Management
Nevada
$3.04M -$2.86M -1,326,569 -47%
Jane Street
7
Jane Street
New York
$2.21M +$1.47M +684,738 +168%
Pathstone Holdings
8
Pathstone Holdings
New Jersey
$2.1M +$36.7K +17,040 +2%
Morgan Stanley
9
Morgan Stanley
New York
$1.58M -$4.71M -2,187,192 -74%
LPC
10
Lion Point Capital
New York
$1.53M +$208K +96,447 +15%
Toronto Dominion Bank
11
Toronto Dominion Bank
Ontario, Canada
$1.51M
BCM
12
Boxer Capital Management
California
$1.35M
SCM
13
Stonepine Capital Management
Oregon
$1.34M +$1.43M +662,666 New
Susquehanna International Group
14
Susquehanna International Group
Pennsylvania
$1.3M +$833K +386,528 +151%
Two Sigma Advisers
15
Two Sigma Advisers
New York
$1.25M +$830K +385,551 +165%
UBS Group
16
UBS Group
Switzerland
$994K +$203K +94,334 +24%
Point72 Asset Management
17
Point72 Asset Management
Connecticut
$974K +$1.04M +482,355 New
Millennium Management
18
Millennium Management
New York
$813K +$2.32K +1,076 +0.3%
Citadel Advisors
19
Citadel Advisors
Florida
$714K -$342K -158,835 -31%
ACA
20
Aptus Capital Advisors
Alabama
$532K +$114K +53,000 +25%
GWANC
21
Guardian Wealth Advisors (North Carolina)
North Carolina
$532K +$114K +53,000 +25%
Squarepoint
22
Squarepoint
New York
$504K +$537K +249,344 New
GCP
23
GSA Capital Partners
United Kingdom
$477K +$339K +157,391 +200%
Nomura Holdings
24
Nomura Holdings
Japan
$455K +$485K +225,000 New
BNP Paribas Financial Markets
25
BNP Paribas Financial Markets
France
$448K +$478K +221,951 New

MIST Hedge Fund Activity: Q4 2025 in Review

79 of the 8,228 institutional investors tracked by Wall St. Rank reported a position in Milestone Pharmaceuticals (MIST) for Q4 2025, worth a combined $53.6M — down 22% from $68.3M a quarter earlier.

Buyers outnumbered sellers: 28 funds opened new MIST positions and 9 closed out — a net gain of 19 holders — while 21 added to existing stakes and 9 trimmed.

The largest buyer was Marshall Wace, adding an estimated $2.65M. The largest seller was Adage Capital Partners, cutting an estimated $8.97M.

  • 79 institutional investors held Milestone Pharmaceuticals (MIST) as of Q4 2025, up from 61 in Q3 2025.
  • Funds reported $53.6M of Milestone Pharmaceuticals stock for Q4 2025, down 22% quarter-over-quarter.
  • 28 funds opened new Milestone Pharmaceuticals positions in Q4 2025 and 9 closed out, a net change of +19 holders.
  • The largest Milestone Pharmaceuticals buyer in Q4 2025 was Marshall Wace, an estimated $2.65M added.
  • The largest Milestone Pharmaceuticals seller in Q4 2025 was Adage Capital Partners, an estimated $8.97M sold.

Based on aggregated 13F filings for Q4 2025.